About CanCell

A worldwide effort to identify genetic and epigenetic aberrations in cancer has yielded enormous
amounts of information that offer unprecedented opportunities for cancer diagnosis and therapy. A
major obstacle to translating this information into clinical benefit is our incomplete understanding
of the molecular mechanisms by which irreversible genetic aberrations and reversible epigenetic
modifications affect tumor cells, and how the tumor microenvironment and somatic tissues promote
cancer progression. These mechanisms can only be unraveled through functional studies of welldefined
cancer models at the cellular and whole-organism level. CanCell will elucidate changes in
cellular pathways that are rewired during cancer development, defined as “cancer cell programs”,
and target these for establishing novel concepts in cancer therapy.


Harald Stenmark (director), Institute for Cancer Research, Oslo University Hospital, and Institute for Clinical Medicine, University of Oslo